Health Care & Life Sciences » Biotechnology | Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
33,947.00
75,777.00
118,181.00
109,577.00
128,984.00
178,407
Depreciation, Depletion & Amortization
144.00
323.00
634.00
717.00
713.00
735
Other Funds
-
-
-
39.00
-
18,724
Funds from Operations
29,930.00
61,162.00
98,712.00
85,378.00
106,679.00
158,948
Changes in Working Capital
360.00
9,715.00
4,683.00
987.00
32,962.00
169
Net Operating Cash Flow
30,290.00
51,447.00
94,029.00
84,391.00
73,717.00
159,117
Capital Expenditures
57.00
2,834.00
1,416.00
70.00
62.00
Purchase/Sale of Investments
-
63,797.00
89,407.00
24,665.00
17,170.00
Net Investing Cash Flow
57.00
67,031.00
90,823.00
24,595.00
17,108.00
Net Financing Cash Flow
185,930.00
113,121.00
92,700.00
51,164.00
75,743.00
Net Change in Cash
155,583.00
5,365.00
92,251.00
8,695.00
19,334.00
Free Cash Flow
30,347.00
54,281.00
95,445.00
84,461.00
73,779.00
Change in Capital Stock
185,930.00
113,121.00
92,700.00
51,203.00
75,743.00
Exchange Rate Effect
-
8.00
99.00
63.00
200.00
Other Uses
-
400.00
-
-
-

About Karyopharm Therapeutics

View Profile
Address
85 Wells Avenue
Newton Massachusetts 02459
United States
Employees -
Website http://www.karyopharm.com
Updated 07/08/2019
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.